CI

Molina (MOH) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.84 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +23.61%. A quarter ago, it was expected that this provider of Medicaid-related services would post earnings of $1.37 per share when it actually produced earnings of $1.51, delivering a surprise of +10.22%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Molina, which belongs to the Zacks Medical - HMOs industry, posted revenues of $11.08 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 1.42%. This compares to year-ago revenues of $11.48 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Molina shares have added about 26.6% since the beginning of the year versus the S&P 500's gain of 12.7%. While Molina has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Molina was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.69 on $12 billion in revenues for the coming quarter and $5.28 on $44.47 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the top 19% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Cigna (CI), has yet to report results for the quarter ended September 2026. The results are expected to be released on November 5. This health insurer is expected to post quarterly earnings of $7.46 per share in its upcoming report, which represents a year-over-year change of -4.7%. The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. Cigna's revenues are expected to be $73.53 billion, up 5.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Molina Healthcare, Inc (MOH) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

The Cigna Group (NYSE:CI) brings together its Cigna Healthcare insurance business and Evernorth Health Services, which covers pharmacy benefit management and specialty pharmacy operations. By diversifying its business in this way, Cigna can generate earnings from several sources. As a result, we added the company to our best blue-chip dividend stocks list. However, the company still faces challenges such as regulatory scrutiny, pricing pressure, and rising healthcare costs. In the second quarter of 2026, Cigna's revenue grew 7% from the previous year, reaching $71.7 billion. Adjusted earnings per share (EPS) climbed to $7.78, up from $7.20, and net income came in at $1.66 billion. Management expressed their confidence in continued growth by raising the 2026 adjusted EPS outlook to at least $30.45.Even with stronger earnings, some risks remain. For example, Cigna Healthcare's medical care ratio increased to 84.5% from 83.2% a year earlier, which means medical costs took up a larger portion of premiums. Evernorth is also dealing with regulatory pressure on pharmacy benefit management and could see its margins squeezed as the industry changes how it handles rebates and drug pricing. The Cigna Group (NYSE:CI) trades at a forward P/E ratio of 8.26, compared to a trailing P/E of 11.41. This difference shows that the market expects Cigna's earnings to rise. With a forward P/E of 8.26, the implied earnings yield is around 12.1%, compared with the 10-year U.S. Treasury yield of 5.21% on October 13, 2026. This represents a spread of approximately 6.9 percentage points, although equity earnings are uncertain and do not represent guaranteed cash returns. Of course, equity earnings aren't guaranteed cash returns, so this kind of comparison is more illustrative than direct. Cigna's valuation has narrowed over time. According to Yahoo's data, its forward P/E was 11.26 in June 2025 and dropped to 8.87 by September 2025. Right now, Cigna's forward P/E is lower than CVS Health's 10.67, which suggests that Cigna is trading at a relative discount. However, it's important to keep in mind that the two companies differ in their business mix and risk profiles, which can affect direct comparisons. Read their valuation analysis here: CVS Health (CVS) vs Cigna (CI): Which is a Better Stock to Buy? With a forward P/E of 8.26, it seems the market isn't entirely convinced that Cigna's current earnings growth will last. Management's adjusted EPS floor of $30.45 suggests a forward multiple of about 9.3 at the latest share price of $282.53. This discount could present an opportunity if Evernorth continues to grow and medical costs stabilize. On the other hand, the low multiple might be warranted if regulatory changes or pressures on pharmacy benefit margins start to eat into profits. Since Cigna's net profit margin is only about 2.3%, there's not much room for large shocks to the business. The Cigna Group (NYSE:CI) offers an annualized dividend of $6.24 per share, which works out to a 2.20% yield and a payout ratio of 25.38%. Because this payout is relatively modest, there's room for Cigna to increase it in the future, and it also helps cushion the company if earnings take a hit. While billionaires are showing interest in CI as a dividend stock, three other stocks rank even higher on their radars. Find more here. For investors, the dividend should be seen as just one piece of the total return, rather than the main reason to buy the stock. Share price gains, earnings growth, and stock buybacks might play a bigger role, although none of these are guaranteed. Cigna's low forward multiple, solid implied earnings yield, and manageable dividend payout make it a stock to consider for both income and growth potential. However, the main question is whether the company can sustain its earnings at the current level. Investors should keep an eye on trends in medical costs, Evernorth's profit margins, and any regulatory changes before viewing the stock's discounted valuation as a chance for upside rather than a warning sign about risk. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Lowe's Dividend Sustainability Looks Solid, but Returns Face a Test and Accenture's Valuation Reset Creates an Opportunity, but AI Remains a Risk This article is originally published at Insider Monkey.

Headquartered in Bloomfield, Connecticut, The Cigna Group (CI) is a global health company focused on improving health and vitality. Through its Cigna Healthcare and Evernorth Health Services businesses, the company serves more than 185 million customer relationships across over 30 markets and jurisdictions. CI has a market capitalization of $74.6 billion. CI is scheduled to report its Q3 earnings on Thursday, November 5, 2026, before the market opens. Ahead of the release, analysts expect diluted EPS of $7.46, down 4.7% from $7.83 in the year-ago quarter. However, CI has exceeded Wall Street's EPS estimates in each of the past four quarters, demonstrating a consistent track record of earnings outperformance. - Elon Musk Sets the Record Straight on Terafab. What It Means for Intel, TSMC, and SpaceX Stocks. - Why Super Micro Stock Is Heading to $60 - A $1.3 Billion Reason Why IONQ Stock Is Down Today - Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For fiscal 2026, analysts expect CI to report EPS of $30.50, up 2.2% from $29.84 in fiscal 2025. Its EPS is projected to increase another 9.7% to $33.46 in fiscal 2027. CI stock has declined 5.8% over the past 52 weeks, underperforming both the S&P 500 Index ($SPX), which gained 19.2%, and the State Street Health Care Select Sector SPDR ETF (XLV), which advanced 21% over the same period. The Cigna Group faces concerns about customer retention and sustained customer growth, with its customer base declining by an average of 8.1% over the past two years. Nevertheless, the company continues to deliver solid underlying results, with revenue growing at an annual rate of 13.8% over the past two years and EPS increasing by 12% annually over the past five years. Meanwhile, on October 6, Cigna Healthcare introduced Health Sense, a personalized support model designed to improve patient outcomes and affordability by connecting health information, benefits, costs, and clinical expertise. Projected to reduce inefficient healthcare spending by 10% by 2030, the initiative will initially target customers with oncology and cardiometabolic conditions beginning in early 2027. Following the announcement, CI shares rose 1.1%. Analysts remain somewhat bullish on CI, with a consensus "Moderate Buy" rating. Of the 23 analysts covering the stock, 14 recommend a "Strong Buy," three suggest a "Moderate Buy," and six rate it a "Hold." The average analyst price target of $342.26 represents a 20.8% premium to the current share price. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Cigna Group has delivered a mixed run in recent years, and investors now have to decide whether the current US$275.26 share price lines up with what its earnings justify. The question is whether that price fairly reflects what the business is generating today, rather than just where the stock has traded before. - Over the past 5 years the stock has gained about 50.0%, which puts real weight on whether the underlying earnings profile can support that kind of long term outcome. - The business relies heavily on its ability to turn premiums and fees into consistent profit, so the key issue for valuation is how reliable and sustainable those earnings are through the cycle. - There is a second opinion on Cigna Group worth weighing. See what analysts think Cigna Group's shares could be worth. The stock's next move may depend on whether Cigna Group's current earnings are strong and dependable enough to justify paying around US$275 per share today. If you are weighing Cigna Group purely on what its earnings justify, it can help to benchmark that thinking against a focused list of 32 high quality undervalued stocks as a starting point for further research. The P/E ratio is a useful way to think about Cigna Group because earnings are a central yardstick for how this insurer creates value for shareholders. On this measure, Cigna Group trades on about 11.3x earnings, which is well below the broader healthcare sector average of roughly 24.2x. Compared with a peer group closer to 29.7x, the current price tags the stock at a much lower earnings multiple than many other healthcare players. The tailored fair P/E implied by the model, which factors in Cigna Group's profitability profile, sector, size and risk, points to a higher level than where the shares trade today. That gap suggests the current P/E may reflect a discount rather than a premium, although you still need to judge whether the quality and resilience of those earnings fit your own risk tolerance. Explore the numbers behind Cigna Group's P/E valuation. Simply Wall St Narratives pick up where Cigna Group's valuation puzzle leaves off, by spelling out which future paths for growth, margins and earnings would need to hold for the shares to be worth materially more or less than today's price. Rather than relying on a single P/E or model point estimate, each narrative lays out the assumptions behind its view of fair value so you can compare those expectations with Cigna Group's reported results as they come through. One of the top community narratives on Cigna Group: 19% undervalued "Cigna Group is capitalizing on the growing demand for specialty pharmacy and care services, with recent 22% pretax earnings growth in Specialty & Care Services..." Discover why this Narrative puts Cigna Group at 19% undervalued. Numbers tell part of the story, but the executives steering Cigna Group and the way their pay is structured can heavily influence how those numbers evolve over time. See who runs Cigna Group and how they are paid. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CI. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures. The rebound came from repricing, not from growth. Year-over-year revenue growth ran above 12% for two quarters, then slowed to 2.0% and to 0.4% in the latest quarter. Second-quarter revenue of $112 billion was largely in line with a year earlier, yet operating earnings grew to $8 billion. Management credits the pricing, benefit design and market actions it has taken over the past year. Medicare Advantage membership is shrinking as well, and the company expects that enrollment to fall by about 1.1 million in 2026. With sales this flat, earnings per share grow only if margins widen or the share count falls. Management still stands by a long-term earnings growth rate of 13% to 16%, and the CEO says that rate includes productivity gains and use of capital. Margin is exactly where the pressure sits. In commercial plans, medical cost trend is running modestly above 11%, and management says it sees no evidence of moderation yet. One primary driver, by the company's own account, is the arbitration process under the No Surprises Act, which applies only to commercial plans. Management says that process adds about 50 basis points of extra trend in 2026. When arbiters side with out-of-network providers, the average payout is now 11 times what Medicare would pay. Management says the sticky trend is pushing full commercial margin recovery past 2027. Medicare looks better, with trend below plan. Yet management says that is not an inflection point: trend there is continuing at high levels, and its 2027 planning expects no meaningful let-up. In Medicaid, rate increases of around 6% to 7% are still lagging medical trend. Worried enough to watch closely. UnitedHealth can keep growing earnings on flat sales only while its pricing stays ahead of medical cost trend, and in commercial plans that trend shows no sign of easing yet. Management calls the commercial repair a multi-year journey, so this risk will not arrive as one bad headline. Instead, it plays out gradually as contracts reprice against claims. The starting point also had help. Second-quarter results included $860 million of net favorable prior-period medical development, about a tenth of that quarter's operating earnings. Most of that reserve adjustment stemmed from earlier quarters in 2026 rather than from prior years. Management says the $19.50 to $20 guide is still the right base even though it reflects that development, and that nothing needs carving out. The numbers to watch arrive with third-quarter 2026 results: whether commercial cost trend is still above 11%, and the fresh Medicare trend estimate management has said will probably come then. Options traders are not pricing unusual stress for now, with implied volatility in the 40th percentile of its past year. Our implied volatility screen shows how large a move the market expects, and that can change quickly. That depends on what else you hold, because a cost problem like this one surfaces quietly, one report at a time. Weighing it across everything you own is the work the Trefis High Quality Portfolio is built to do. That portfolio has a track record of outpacing the three major indices.

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Cigna Group stock has delivered a 44.4% gain over the past five years, yet the broader valuation checks still suggest the shares screen as undervalued at the recent price of US$277.51. With shorter term returns weaker, investors are left weighing a mixed share price history against a still supportive valuation read. Over five years, Cigna Group has returned 44.4%, which points to solid long term wealth creation despite more recent share price softness. Expectations for the company to keep generating dependable cash flows from its health insurance and related services can support the current valuation. At the same time, any pressure on medical cost trends or pricing power may limit how much investors are willing to pay for that cash flow stream. Cigna Group screens as undervalued on the broader checks, with the company passing 6 of 6 valuation tests, which leans in favor of the stock being priced below what those metrics suggest is reasonable. The issue now is whether that high value score and longer term return justify taking the recent share price weakness as an opportunity or a warning sign on Cigna Group. Find out why Cigna Group's -6.8% return over the last year is lagging behind its peers. The P/E ratio is a useful way to look at Cigna Group because earnings are a key driver for how investors typically assess large health insurers. On this measure, Cigna Group trades on a P/E of about 11.4x, which is well below the wider Healthcare sector average of roughly 25.5x and the peer group average near 31.6x. The tailored fair P/E ratio for Cigna Group is estimated at about 28.7x, which is more than double the current multiple. That gap suggests the stock is pricing in a much lower earnings valuation than what the fair ratio implies based on the company’s profile and risk factors. Investors watching Cigna Group may see this as a sign that the market is applying a cautious earnings multiple compared with both sector benchmarks and this model’s fair value yardstick. Overall, the P/E comparison indicates that Cigna Group stock appears undervalued on this earnings multiple. See what the numbers say about this price — find out in our valuation breakdown. Simply Wall St Narratives for Cigna Group pick up where this valuation puzzle leaves off and spell out what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than today’s price. Each narrative presents Cigna Group's fair value as a thesis about the business that you can revisit over time, and they are available on the company’s Community page for investors who want that extra layer of structure. You can share your own narrative on Cigna Group's growth, margins and execution and set out a clear, number-driven case that others in the community can follow over time. Add your voice to the Simply Wall St community and see how your thesis tracks as new results arrive. Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying! Cigna Group screens as undervalued on earnings compared with both its sector and peer averages, which leaves the debate centered on why the market is keeping the P/E multiple this low. The key question is whether concerns around medical cost trends and pricing power prove persistent enough to justify that discount. If those pressures remain contained, a re rating of the multiple becomes the crux of the upside case. If they intensify, the current valuation may simply reflect a market that is correctly cautious rather than mispricing Cigna Group stock. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CI. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

CVS Health CVS is entering the second half of 2026 with stronger earnings momentum, higher cash generation and an improved Aetna profit outlook. Those gains strengthen the recovery case after a difficult period for the insurer. The trade-off is that medical-cost pressure and changing pharmacy benefit manager economics remain unresolved. CVS trades below major valuation benchmarks, but its multiple is already above its own five-year median. The Zacks Consensus Estimate for 2026 earnings has increased 7.9% over the prior four weeks, while projected 2026 EPS growth stands at 16.6%. Current cash flow growth of 65.3% adds another positive signal. Second-quarter results support that trend. Adjusted EPS increased 42.5% year over year to $2.58, while adjusted operating income rose 35.4% to $5.16 billion. CVS also raised 2026 adjusted EPS guidance to $7.90-$8.10. Image Source: Zacks Investment Research CVS trades at 11.7X forward 12-month earnings, below the Zacks sub-industry's 16.2X and the S&P 500's 20.8X. The gap shows that investors still assign CVS a sizable discount despite improving earnings. Image Source: Zacks Investment Research The stock is less cheap against its own history. CVS' five-year median forward multiple is 10.3X, below the current level. Relative valuation is favorable, but the shares are not unusually inexpensive compared with their historical norm. Health Care Benefits is the clearest operating reason for greater confidence. Adjusted operating income increased by more than $2 billion year over year in the first half of 2026 as pricing discipline and medical-cost management improved profitability. CVS raised the segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above prior guidance. The medical benefit ratio improved to 87.4% in the second quarter from 89.9% a year earlier, showing measurable progress in the margin-recovery plan. The recovery still faces pressure from elevated medical utilization and reimbursement changes. CVS continues to take a prudent view of second-half medical costs, while retail pharmacy and pharmacy services face reimbursement and client-pricing pressure. Caremark adds uncertainty. Weaker 340B conditions are expected to create a 2027 earnings headwind, while management anticipates lower pharmacy benefit manager membership next year. Specialty pharmacy and generic opportunities may offset part of that pressure, but uneven earnings remain possible. The Cigna Group CI is relevant because its Evernorth Health Services business includes pharmacy benefit and related health-service operations. Cigna therefore offers another diversified model exposed to benefit-management economics. UnitedHealth Group UNH combines a large insurance franchise with health-services operations through Optum. It provides another useful reference point for investors assessing medical-cost and health-services trends across managed care. The bottom line is that CVS has better earnings momentum and a favorable relative valuation, but execution risk remains. Aetna is improving, while medical utilization, reimbursement pressure and Caremark's 2027 reset argue for more evidence that the gains can persist. CVS currently carries a Zacks Rank #3 (Hold), which fits that mixed setup rather than signaling an aggressive entry point. The stock also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those scores indicate favorable characteristics across several styles, but they are designed to complement the Zacks Rank. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q2 health insurance providers earnings season. Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care. The 12 health insurance providers stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.8% while next quarter’s revenue guidance was 1.7% below. While some health insurance providers stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 3.1% since the latest earnings results. With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE:CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans. Cigna reported revenues of $71.56 billion, up 6.6% year on year. This print exceeded analysts’ expectations by 1.2%. Overall, it was a satisfactory quarter for the company with a beat of analysts’ EPS estimates. Even though it had a relatively good quarter, the market seems discontent with the results. The stock is down 4.8% since reporting and currently trades at $282.28. Is now the time to buy Cigna? Access our full analysis of the earnings results here, it’s free. With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE:CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary. CVS Health reported revenues of $106.1 billion, up 7.3% year on year, outperforming analysts’ expectations by 6.7%. The business had an incredible quarter with a beat of analysts’ EPS estimates and a solid beat of analysts’ full-year EPS guidance estimates. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 7% since reporting. It currently trades at $97.16. Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it’s free. Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ:PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services. Progyny reported revenues of $350.5 million, up 5.3% year on year, exceeding analysts’ expectations by 0.6%. Still, it was a slower quarter as it posted EBITDA guidance for next quarter missing analysts’ expectations significantly and full-year revenue guidance slightly missing analysts’ expectations. Progyny delivered the weakest guidance update in the group. As expected, the stock is down 13% since the results and currently trades at $26.29. Read our full analysis of Progyny’s results here. Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ:CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care. Clover Health reported revenues of $743.2 million, up 55.6% year on year. This number beat analysts’ expectations by 2%. It was an exceptional quarter as it also produced a beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations. The company added 1,536 customers to reach a total of 157,309. The stock is up 10.6% since reporting and currently trades at $4.58. Read our full, actionable report on Clover Health here, it’s free. Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE:MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states. Molina Healthcare reported revenues of $10.87 billion, down 4.8% year on year. This result was in line with analysts’ expectations. Zooming out, it was a slower quarter as it recorded full-year revenue guidance missing analysts’ expectations significantly. Molina Healthcare had the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers. The company lost 108,000 customers and ended up with a total of 4.93 million. The stock is down 4.1% since reporting and currently trades at $212.75. Read our full, actionable report on Molina Healthcare here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

CVS Health CVS raised its 2026 earnings and cash-flow outlook after a second quarter marked by stronger profitability across all operating segments. The improvement gives the company more room to rebuild margins after a difficult period for its Aetna insurance business. The recovery is gaining traction, but the path is not risk-free. Medical-cost pressure, reimbursement changes and a changing pharmacy benefit manager environment could still test the durability of the higher outlook. Second-quarter adjusted earnings rose 42.5% year over year to $2.58 per share, while revenues increased 7.3% to $106.10 billion. Adjusted operating income advanced 35.4% to $5.16 billion, reflecting gains across all operating segments. Health Care Benefits delivered the largest earnings improvement, while Health Services and Pharmacy & Consumer Wellness also posted higher adjusted operating income. That broader contribution matters because the recovery is not resting on a single business line. CVS lifted its 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50. The company now expects consolidated revenues of at least $414 billion and adjusted operating income of $16.58-$16.92 billion. Here’s where consensus estimates for the company’s revenues and earnings currently stand. Image Source: Zacks Investment Research Expected cash flow from operations also rose to at least $11.5 billion from at least $9.5 billion. The stronger cash outlook supports further leverage improvement after the company ended the second quarter with a leverage ratio of about 3.5 times. Aetna's Health Care Benefits business is becoming a larger earnings contributor as pricing discipline and medical-cost management improve results. Second-quarter adjusted operating income reached $2.43 billion, up 85.5% year over year, while the medical benefit ratio improved to 87.4% from 89.9%. CVS raised the segment's 2026 adjusted operating income outlook to $5.03-$5.37 billion, more than $1 billion above its prior guidance. Management expects the full-year medical benefit ratio to be about 89.75%, plus or minus 25 basis points, while continuing to take a prudent view of second-half medical costs. The higher outlook does not remove execution risk. CVS expects the Health Care Benefits medical benefit ratio to rise materially through the second half, while reimbursement pressure continues in retail pharmacy and pharmacy services. Weakness in the 340B business is also expected to create a 2027 headwind. Caremark faces another transition as regulatory changes and the shift toward net-cost pricing reshape pharmacy benefit manager economics. Management also expects lower Caremark membership in 2027 as it takes a more disciplined approach to contract renewals and some health-plan clients exit products or markets. Peer results show that managed-care and pharmacy-services operators are also adjusting to changing cost and contracting conditions. UnitedHealth Group UNH raised its 2026 adjusted earnings outlook after its second quarter, while The Cigna Group CI increased its 2026 adjusted income outlook after reporting year-over-year revenue and earnings growth. CVS has clearer operating momentum than it did a year ago, led by Aetna's margin recovery, stronger pharmacy execution and higher cash generation. Still, the second-half medical-cost trajectory and 2027 pharmacy-services headwinds argue for a measured view rather than assuming the recovery is complete. The stock currently carries a Zacks Rank #3 (Hold). CVS also has a Value Score of A, Growth Score of A, Momentum Score of A and VGM Score of A. Those favorable Style Scores point to attractive characteristics across valuation, growth and momentum, but the Zacks Rank keeps the near-term signal balanced as investors assess whether the higher guidance can translate into sustained. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total shareholder return of 47.06% reflects a stronger longer term outcome. If this healthcare update has you thinking about where else growth and efficiency could meet, it may be worth scanning 43 healthcare AI stocks for other potential ideas in the sector. With Cigna Group shares only modestly ahead this year after fresh earnings and a long running buyback, the question now is whether to treat the recent uptick as a workable entry point or to wait for a cheaper setup. Cigna Group closed at $282.49 compared to a narrative fair value of $340.92, which frames the stock as materially undervalued on that view. Read the complete narrative. Want to see what this potential specialty pharmacy tailwind means for Cigna Group's earnings path and profit multiple assumptions? The full narrative unpacks how expected revenue trends, margin shifts and share count changes all connect to that $340.92 fair value and the implied discount rate story. Result: Fair Value of $340.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also need to weigh Cigna Group’s heavy reliance on the Evernorth PBM model and ongoing regulatory scrutiny, which could pressure margins and future contract wins. Find out about the key risks to this Cigna Group narrative. With both risks and rewards in play for Cigna Group, it makes sense to review the numbers yourself and decide quickly where you stand. To see a concise summary of the key concerns alongside the potential upsides that investors are watching, start with 6 key rewards and 1 important warning sign. If Cigna Group has sharpened your focus on quality, now is the moment to widen your search and line up a few fresh ideas before the next move. Spot potential mispricings early and compare them with your watchlist using the 51 high quality undervalued stocks. Strengthen your income stream by reviewing companies that feature in the 8 dividend fortresses. Reduce portfolio stress and focus on resilience by exploring the 79 resilient stocks with low risk scores. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CI. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]